vTv Therapeutics(US:VTVT) Yahoo Finance·2026-03-18 00:05Core Insights - vTv Therapeutics Inc. reported a net loss of $27 million for the full year 2025, with R&D expenses increasing to $17.9 million due to investments in clinical trials for cadisegliatin [1][5] - The company is advancing cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes, and has initiated patient dosing in the Phase 3 CATT1 trial [2][5] - A licensing agreement with Newsoara Biopharma Inc. was expanded, granting exclusive worldwide rights to vTv's PDE4 inhibitor, HPP737, for a $20 million upfront payment and potential future milestones totaling up to $115 million plus royalties [3] Financial Performance - vTv Therapeutics reported a net loss of $27 million for 2025 [1][5] - R&D expenses rose to $17.9 million, reflecting increased investment in clinical trials [1] Clinical Development - The company initiated patient dosing in the Phase 3 CATT1 trial and expanded its scientific advisory board with recognized experts [2] - Despite slower-than-expected patient recruitment, vTv increased its clinical site count and engagement efforts, expecting to complete enrollment for the CATT1 trial in Q3 2026 [2] Licensing and Partnerships - An expansion of the licensing agreement with Newsoara Biopharma Inc. was noted, providing exclusive rights to HPP737 in exchange for a $20 million upfront payment and potential future milestones [3] - vTv submitted a Phase 2 clinical study protocol for cadisegliatin to evaluate its efficacy and safety in type 2 diabetes patients, marking a significant step in international research efforts [3]